{"id":"https://genegraph.clinicalgenome.org/r/fbee0da0-c433-4c50-a2cf-baa31f09b5c1v1.0","type":"EvidenceStrengthAssertion","dc:description":"The *DAAM2* gene is located on chromosome 6 at 6p21.2 and encodes the protein 'dishevelled associated activator of morphogenesis 2'. DAAM2 is expressed on podocytes in the kidney and is thought to potentially regulate podocyte apoptosis, adhesion, and migration through several cell signaling pathways (PMID: 33544843). \n\n*DAAM2* was first reported in relation to autosomal recessive nephrotic syndrome type 24 in 2020 (Schneider et al., PMID: 33232676). Nephrotic syndrome type 24 (OMIM:619263) is characterized by proteinuria, hypoalbuminemia, edema, and hyperlipidemia. There is also usually a lack of response to corticosteroid treatment. The mechanism of pathogenicity is known to be loss of function.\n \nEight variants (6 missense and 2 nonsense) have been reported in six probands in three publications (PMIDs: 33232676, 36646731, 38860410) and are included in this curation. A total of 5.2/12 pts. for genetic evidence was reached. \nThis gene-disease relationship is also supported by expression (PMID: 33232676), protein interaction with INF2 (PMID: 33232676) and a *daam2* knock out model using Xenopus embryos resulting in abnormal kidney morphology (PMID: 33232676). A total of 1.5/6 pts. for experimental evidence was reached.\n\nIn summary, there is limited evidence supporting the relationship between *DAAM2* and nephrotic syndrome type 24. This gene-disease pair was originally evaluated by the ClinGen Glomerulopathy GCEP on 05.08.2023 (SOP Version 9). It was reevaluated on 07.23.2024 (SOP Version 10). As a result of this reevaluation, the classification did not change.","dc:isVersionOf":"https://genegraph.clinicalgenome.org/r/fbee0da0-c433-4c50-a2cf-baa31f09b5c1","GCISnapshot":"https://genegraph.clinicalgenome.org/r/0190c635-fa58-432c-9342-68805f6cbca2","calculatedEvidenceStrength":"Moderate","contributions":[{"id":"https://genegraph.clinicalgenome.org/r/0190c635-fa58-432c-9342-68805f6cbca2_publish_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10068","date":"2024-12-16T17:22:48.424Z","role":"Publisher"},{"id":"https://genegraph.clinicalgenome.org/r/0190c635-fa58-432c-9342-68805f6cbca2_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10068","date":"2024-07-23T16:00:00.000Z","role":"Approver"}],"curationReasonDescription":"The curation does not quite reach 7 points and so has been rounded down to the Limited classification.","curationReasons":["NewCuration"],"evidence":[{"id":"https://genegraph.clinicalgenome.org/r/0190c635-fa58-432c-9342-68805f6cbca2_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/e3b4f274-5dd8-4075-b3e7-787874221fa7_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/95f9c552-a1ba-4def-bb39-041e09b55a7d","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/95f9c552-a1ba-4def-bb39-041e09b55a7d_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Using fluorescent live imaging, it was shown that overexpression of the cDNA with this missense variant (GFP-tagged) in a human podocyte cell line led to decreased filopodia formation. Additionally, a scratch assay demonstrated impaired podocyte migration.\n","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/95f9c552-a1ba-4def-bb39-041e09b55a7d_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33232676","allele":{"id":"https://genegraph.clinicalgenome.org/r/3b14e955-4359-46aa-a565-a84d4fa45243","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001201427.2(DAAM2):c.1745C>A (p.Pro582His)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA3795038"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/5264572c-3982-4a71-b003-d13e1975c46a","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/5264572c-3982-4a71-b003-d13e1975c46a_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Using fluorescent live imaging, it was shown that overexpression of the cDNA with this missense variant (GFP-tagged) in a human podocyte cell line led to decreased filopodia formation. Additionally, a scratch assay demonstrated impaired podocyte migration.\n","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/5264572c-3982-4a71-b003-d13e1975c46a_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33232676","allele":{"id":"https://genegraph.clinicalgenome.org/r/be5b4e4e-2349-4f77-ace5-318b9d7b300b","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001201427.2(DAAM2):c.361G>C (p.Glu121Gln)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA364029783"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/e3b4f274-5dd8-4075-b3e7-787874221fa7","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33232676","rdfs:label":"A3174-21","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":2,"allele":[{"id":"https://genegraph.clinicalgenome.org/r/be5b4e4e-2349-4f77-ace5-318b9d7b300b"},{"id":"https://genegraph.clinicalgenome.org/r/3b14e955-4359-46aa-a565-a84d4fa45243"}],"firstTestingMethod":"Exome sequencing","phenotypes":["obo:HP_0000097","obo:HP_0031266"],"sex":"Male","variant":[{"id":"https://genegraph.clinicalgenome.org/r/95f9c552-a1ba-4def-bb39-041e09b55a7d_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/5264572c-3982-4a71-b003-d13e1975c46a_variant_evidence_item"}]}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":1.0},{"id":"https://genegraph.clinicalgenome.org/r/4bdb1fcb-9903-4658-887f-50f9e4f55ce3_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/56be0f01-60bb-4efd-b264-745bfd524b46","type":"EvidenceLine","dc:description":"These homozygous variants have a total score of 0.6 (0.2 + 0.4) but has been converted to 0.25pts each to work within the restrictions of the GCI.","calculatedScore":1.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/56be0f01-60bb-4efd-b264-745bfd524b46_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Using fluorescent live imaging, it was shown that overexpression of the cDNA with this missense variant (GFP-tagged) in a human podocyte cell line led to decreased filopodia formation. Additionally, a scratch assay demonstrated impaired podocyte migration.","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/56be0f01-60bb-4efd-b264-745bfd524b46_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33232676","allele":{"id":"https://genegraph.clinicalgenome.org/r/ac576e94-0b0d-481b-881a-43a2e541c25a","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001201427.2(DAAM2):c.1004G>A (p.Arg335Gln)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA3794840"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/4bdb1fcb-9903-4658-887f-50f9e4f55ce3","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33232676","rdfs:label":"B1068-21","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":5,"allele":{"id":"https://genegraph.clinicalgenome.org/r/ac576e94-0b0d-481b-881a-43a2e541c25a"},"firstTestingMethod":"Exome sequencing","phenotypes":["obo:HP_0000097","obo:HP_0000846","obo:HP_0031266"],"sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/56be0f01-60bb-4efd-b264-745bfd524b46_variant_evidence_item"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/19939118-9703-4e3b-9fab-f174149e9f5c_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/c8733617-56d1-4373-98ff-91ae8959c472","type":"EvidenceLine","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/c8733617-56d1-4373-98ff-91ae8959c472_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/36646731","allele":{"id":"https://genegraph.clinicalgenome.org/r/10fe5ebd-fd9f-4859-b698-d092fcc479be","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001201427.2(DAAM2):c.803G>A (p.Arg268Gln)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA137619543"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/60aeb5c3-07a5-4c71-990c-9ce7c4701639","type":"EvidenceLine","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/60aeb5c3-07a5-4c71-990c-9ce7c4701639_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/36646731","allele":{"id":"https://genegraph.clinicalgenome.org/r/725d5cc7-15a3-4c6b-b383-b9e325f45189","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001201427.2(DAAM2):c.602T>C (p.Ile201Thr)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA364030329"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/19939118-9703-4e3b-9fab-f174149e9f5c","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/36646731","rdfs:label":"G6787","ageType":"AgeAtDiagnosis","ageUnit":"Years","ageValue":8,"allele":[{"id":"https://genegraph.clinicalgenome.org/r/725d5cc7-15a3-4c6b-b383-b9e325f45189"},{"id":"https://genegraph.clinicalgenome.org/r/10fe5ebd-fd9f-4859-b698-d092fcc479be"}],"firstTestingMethod":"Exome sequencing","phenotypes":"obo:HP_0000093","sex":"Female","variant":[{"id":"https://genegraph.clinicalgenome.org/r/60aeb5c3-07a5-4c71-990c-9ce7c4701639_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/c8733617-56d1-4373-98ff-91ae8959c472_variant_evidence_item"}]}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0.2},{"id":"https://genegraph.clinicalgenome.org/r/32cfdcc1-e7ad-4a5b-a4b3-d3e44e1612bd_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/1d936faa-5303-4bdc-833c-07ba14f8d0b8","type":"EvidenceLine","dc:description":"Concern over phenotypic match","calculatedScore":3.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/1d936faa-5303-4bdc-833c-07ba14f8d0b8_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/38860410","allele":{"id":"https://genegraph.clinicalgenome.org/r/ca6b02ec-cf60-4ba1-ae7c-933eed6af475","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001201427.2(DAAM2):c.196C>T (p.Arg66Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA137770969"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/32cfdcc1-e7ad-4a5b-a4b3-d3e44e1612bd","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/38860410","rdfs:label":"Family 5 proband","ageType":"AgeAtOnset","ageUnit":"Months","ageValue":9,"allele":{"id":"https://genegraph.clinicalgenome.org/r/ca6b02ec-cf60-4ba1-ae7c-933eed6af475"},"firstTestingMethod":"Exome sequencing","phenotypeFreeText":"Increased thickness of skull bones, modeling defect of the metacarpals and osteopenia of the long bones, Atlantoaxial instability, flat supra orbital ridges, midface hypoplasia, low set ears with overfolded helices","phenotypes":["obo:HP_0004322","obo:HP_0000545","obo:HP_0000278"],"secondTestingMethod":"Sanger sequencing","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/1d936faa-5303-4bdc-833c-07ba14f8d0b8_variant_evidence_item"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/0b71b161-d144-4947-9854-e9e681f31530_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/a3a92e40-6c83-40e0-816a-ab2420f5364d","type":"EvidenceLine","dc:description":"These homozygous variants have a total score of 3.5 (1.5 + 1.5 + 0.5) but totaled to 3 points (max for a LoF variant).","calculatedScore":4,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/a3a92e40-6c83-40e0-816a-ab2420f5364d_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Injection of Xenopus embryos using human mRNA with WT or missense DAAM2 variants restores wt1 signal (marker of restored glomus development). Whereas injection of this LoF variant did not restore signal.\n","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/a3a92e40-6c83-40e0-816a-ab2420f5364d_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33232676","allele":{"id":"https://genegraph.clinicalgenome.org/r/0cfbbf7d-9e96-4d3f-8865-a70aa1f6d5b2","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001201427.2(DAAM2):c.1333C>T (p.Arg445Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA364033846"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":3.0},{"id":"https://genegraph.clinicalgenome.org/r/0b71b161-d144-4947-9854-e9e681f31530","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33232676","rdfs:label":"HN-F629","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":15,"allele":{"id":"https://genegraph.clinicalgenome.org/r/0cfbbf7d-9e96-4d3f-8865-a70aa1f6d5b2"},"firstTestingMethod":"Exome sequencing","phenotypes":["obo:HP_0000097","obo:HP_0031266","obo:HP_0004719"],"sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/a3a92e40-6c83-40e0-816a-ab2420f5364d_variant_evidence_item"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":3.0},{"id":"https://genegraph.clinicalgenome.org/r/d40d8e8c-b046-417c-b762-c73afcae7281_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/548abfd7-2019-49d9-a538-f2cd0b29d307","type":"EvidenceLine","dc:description":"These homozygous variants have a total score of 0.6 (0.2 + 0.4) but has been converted to 0.25pts each to work within the restrictions of the GCI.","calculatedScore":1.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/548abfd7-2019-49d9-a538-f2cd0b29d307_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Using fluorescent live imaging, it was shown that overexpression of the cDNA with this missense variant (GFP-tagged) in a human podocyte cell line led to decreased filopodia formation. Additionally, a scratch assay demonstrated impaired podocyte migration.","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/548abfd7-2019-49d9-a538-f2cd0b29d307_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33232676","allele":{"id":"https://genegraph.clinicalgenome.org/r/5a46fb03-71c1-472b-bde8-f368e49e1a8a","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001201427.2(DAAM2):c.3083C>T (p.Ser1028Leu)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA3795538"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/d40d8e8c-b046-417c-b762-c73afcae7281","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33232676","rdfs:label":"HN-F25","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":8,"allele":{"id":"https://genegraph.clinicalgenome.org/r/5a46fb03-71c1-472b-bde8-f368e49e1a8a"},"firstTestingMethod":"Exome sequencing","phenotypes":["obo:HP_0031266","obo:HP_0004719","obo:HP_0000097"],"sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/548abfd7-2019-49d9-a538-f2cd0b29d307_variant_evidence_item"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":5.2},{"id":"https://genegraph.clinicalgenome.org/r/0190c635-fa58-432c-9342-68805f6cbca2_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/0190c635-fa58-432c-9342-68805f6cbca2_model_rescue_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/0b99cc94-626f-447c-bc94-e76a869b575d","type":"EvidenceLine","dc:description":"Model system unable to reflect most features of disease in humans","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/fc2cabb9-5037-4d41-a35a-6c472b5e7d6b","type":"Finding","dc:description":"Abnormal kidney formation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33232676","rdfs:label":"KO of DAAM2 in Xenopus embryos","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallModelAndRescueEvidenceCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/0190c635-fa58-432c-9342-68805f6cbca2_functional_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/8e54df24-e13b-4d88-b011-3b0bef9b279b","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/ab49b6d5-effb-4968-9517-4ddee68862e5","type":"Finding","dc:description":"In murine glomerular podocytes DAAM2 partially co-localized with Inverted Formin 2 (INF2).\n\nIn cultured human embryonic kidney cells (HEK293T), DAAM2 and INF2 co-immunoprecipitated.\n","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33232676","rdfs:label":"DAAM2 co-localization with INF2 to podocytes","demonstrates":{"id":"obo:MI_0915"}}],"specifiedBy":"GeneValidityProteinInteractionCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/d5133a2e-8ecb-451b-a681-be3b504461c6","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/59e8a9f8-b9cd-4b42-8ce6-1e4052bb7b5f","type":"Finding","dc:description":"Immunofluorescence revealed expression of DAAM2 in a human cultured podocyte cell line.\nIHC showed immunolocalization of DAAM2 to the glomerulus of human kidney, in a pattern suggesting podocyte localization\n","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33232676","rdfs:label":"DAAM2 Expression","demonstrates":{"id":"cg:GeneExpressionA"}}],"specifiedBy":"GeneValidityGeneExpressionCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallFunctionalEvidenceCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":1.5}],"evidenceStrength":"Limited","sequence":9555,"specifiedBy":"GeneValidityCriteria10","strengthScore":6.7,"subject":{"id":"https://genegraph.clinicalgenome.org/r/NFb6kyhaanw","type":"GeneValidityProposition","disease":"obo:MONDO_0035459","gene":"hgnc:18143","modeOfInheritance":"obo:HP_0000007"},"version":"1.0","websiteLegacyID":"https://genegraph.clinicalgenome.org/r/assertion_0190c635-fa58-432c-9342-68805f6cbca2-","@context":{"@vocab":"https://genegraph.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"https://genegraph.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"https://genegraph.clinicalgenome.org/r/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"},"curationReasons":{"@type":"@vocab","@container":"@set"},"GCISnapshot":{"@type":"@id"},"dc:isVersionOf":{"@type":"@id"},"websiteLegacyID":{"@type":"@id"}}}